Reality Check on Juvenile Idiopathic Arthritis
Market access for juvenile idiopathic arthritis treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, about 70% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: In November 2019, the FDA approved Pfizer Inc.’s Abrilada (adalimumab-afzb) for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis and plaque psoriasis. It is the fifth biosimilar of AbbVie Inc.’s Humira (adalimumab) that the agency has approved
- Key Findings: Manufacturers with franchises across indications often hold contracting power and improved position, which is everything in this market. There is significant opportunity to contract for position
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.